Development of a Screening Tool to Detect and Stage Cachectic Cancer Patients
1 other identifier
observational
56
1 country
1
Brief Summary
The aim of the study is to develop a screenings tool that will enable hospital nurses to detect and stage cancer cachectic patients. The early detection and staging of cancer cachexia will assist the oncology team in providing the cachectic cancer patient tailor-made patient care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2012
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 10, 2012
CompletedFirst Posted
Study publicly available on registry
February 15, 2012
CompletedStudy Start
First participant enrolled
March 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2013
CompletedDecember 3, 2014
March 1, 2012
1.2 years
February 10, 2012
December 2, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
Nutritional Assessment
Patient-Generated Subjective Global Assessment Instrument is a measure for the nutritional status of the participants. The final score of this instruments devides participants into three categories: well-nourished, moderately nourished or suspected malnourished.
4 times in 6 months
Secondary Outcomes (3)
Quality of Life
4 times in 6 months
Anthropometric measurements
4 times in 6 months
Markers of inflammation/metabolic disturbance
4 times in 6 months
Study Arms (1)
Cancer patients
As this is not an intervention study there is only one cohort. Patients that will be included and excluded are described in the eligibility section.
Eligibility Criteria
The population from which the groups or cohorts will be selected (e.g., primary care clinic, community sample, residents of a certain town). (Limit: 1000 characters)
You may qualify if:
- New Diagnosed Patients With Primary Head and Neck Cancer Neoplasms
- New Diagnosed Patients With Metastatic Pancreatic Neoplasms
- New Diagnosed Patients With Metastatic Colonic Neoplasms
You may not qualify if:
- Patients With Other Primary Neoplasms
- Patients Already in Therapy
- Patients With Non-metastatic Colonic or Pancreatic Neoplasms
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Leuven
Leuven, Vlaams Brabant, 3000, Belgium
Biospecimen
The blood sample that will be collected is part of the routine hospital assessment. The biomarkers that will be measured are albumine, creatine, CRP, hemoglobin and Lactate dehydrogenase (LDH).
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ignace Vergote, PhD
Universitaire Ziekenhuizen KU Leuven
Study Design
- Study Type
- observational
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 10, 2012
First Posted
February 15, 2012
Study Start
March 1, 2012
Primary Completion
May 1, 2013
Study Completion
September 1, 2013
Last Updated
December 3, 2014
Record last verified: 2012-03